Jazz Pharmaceuticals

What does Jazz Pharmaceuticals make?
Jazz Pharmaceuticals makes prescription therapies in neuroscience and oncology. Key products include Xywav and Xyrem for sleep disorders (narcolepsy, idiopathic hypersomnia, cataplexy), Epidiolex for seizures associated with epilepsy, Rylaze for acute lymphoblastic leukemia, Zepzelca for small cell lung cancer, Defitelio for hepatic veno-occlusive disease, Vyxeos for acute myeloid leukemia, Modeyso for multiple myeloma, and Ziihera for HER2-positive cancers.

Is Jazz Pharmaceuticals publicly traded?
Yes, Jazz Pharmaceuticals plc is publicly traded on Nasdaq under the ticker symbol JAZZ. The company is incorporated in Ireland and headquartered in Dublin. It has been listed on Nasdaq since its IPO in 2007.

Who founded Jazz Pharmaceuticals?
Jazz Pharmaceuticals was founded in 2005 by Bruce Cozadd, who previously served as Executive Vice President and Chief Operating Officer at ALZA Corporation. Cozadd continues to serve as Chairman and CEO, making him one of the longest-serving founders still leading a major pharmaceutical company.

Where is Jazz Pharmaceuticals headquartered?
Jazz Pharmaceuticals is headquartered in Dublin, Ireland. The company is incorporated in Ireland for tax and regulatory purposes. Its major operational hubs are in Palo Alto, California and Philadelphia, Pennsylvania, with additional offices in Europe and Canada. Manufacturing is conducted at facilities in Ireland, Italy, and the United States.

How many employees does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals employed approximately 2,890 people as of 31 December 2025. The company's workforce is distributed across research and development, manufacturing, commercial operations, and corporate functions.

Who owns Jazz Pharmaceuticals?
Jazz Pharmaceuticals plc is publicly traded on Nasdaq under the ticker JAZZ. The company has a broad institutional shareholder base with no single controlling shareholder. Major shareholders include institutional investors such as Vanguard Group, BlackRock, and State Street Corporation, consistent with the ownership profile of mid-cap pharmaceutical companies.

What is Xywav?
Xywav is Jazz Pharmaceuticals' largest product by revenue, generating $1.66 billion in net sales in 2025. It is a calcium, magnesium, potassium, and sodium oxybate formulation approved for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy and for idiopathic hypersomnia. Xywav contains less sodium than Xyrem, addressing cardiovascular concerns associated with high sodium intake.

Jazz Pharmaceuticals was founded in 2005 by Bruce Cozadd, who previously served as Executive Vice President and Chief Operating Officer at ALZA Corporation, a pharmaceutical company that was acquired by Johnson and Johnson in 2001. Cozadd established Jazz with the goal of acquiring and developing differentiated pharmaceutical products that address unmet medical needs.

The company went public on the Nasdaq in 2007, raising capital to support its growth strategy. Jazz's early growth was driven by Xyrem (sodium oxybate), a treatment for cataplexy and excessive daytime sleepiness in patients with narcolepsy. Xyrem became the company's primary revenue driver and at its peak accounted for the majority of total revenue. The drug's patent protection and limited competition allowed Jazz to build a strong financial foundation.

Jazz made several strategic acquisitions to diversify its portfolio beyond Xyrem. In 2014, Jazz acquired Gentium S.p.A., an Italian biopharmaceutical company, for approximately $1 billion. This acquisition gained Defitelio (defibrotide), a treatment for severe hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation. Also in 2014, Jazz acquired the Americas rights to defibrotide from Sigma-Tau Pharmaceuticals for $75 million upfront plus potential milestone payments.

In 2021, Jazz acquired GW Pharmaceuticals for approximately $7.2 billion, the company's largest acquisition. This deal added Epidiolex (cannabidiol), the first FDA-approved prescription drug derived from cannabis, to Jazz's neuroscience portfolio. Epidiolex treats seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. The GW Pharmaceuticals acquisition significantly expanded Jazz's neuroscience franchise and reduced its dependence on Xyrem.

Jazz has also been building its oncology portfolio through internal development and acquisitions. Rylaze was approved by the FDA in 2021 for acute lymphoblastic leukemia. Zepzelca received accelerated approval from the FDA in 2020 for metastatic small cell lung cancer, and Jazz has been conducting confirmatory trials to support full approval. Ziihera was approved by the FDA in 2024 for HER2-positive biliary tract cancer. Modeyso received FDA approval in 2025 for multiple myeloma.

The company has been investing in research and development to support its pipeline. Jazz's pipeline includes candidates in neuroscience, including SUZETRIGINE (JZP150) for post-traumatic stress disorder and JZP441 for essential tremor, and in oncology, including Zepzelca in earlier lines of therapy for small cell lung cancer.

Jazz publishes sustainability reports and has committed to environmental, social, and governance (ESG) goals. The company's sustainability program covers environmental impact, access to medicine, patient support, and ethical business practices.

In environmental impact, Jazz has been working to reduce its carbon footprint through energy efficiency improvements at its facilities, waste reduction programs, and sustainable manufacturing practices. The company's manufacturing facility in Como, Italy, operated by Gentium, has implemented environmental management systems.

In access to medicine, Jazz operates patient assistance programs in the United States to help patients access its therapies. The company offers copay assistance programs for eligible patients and has a patient support program that provides financial assistance to qualifying patients who cannot afford their medications. However, the high cost of Jazz's therapies has been a subject of scrutiny, particularly for Xyrem and Xywav, which are among the most expensive drugs in the United States on a per-patient basis.

Jazz has been investing in diversity and inclusion initiatives, including increasing the representation of women and underrepresented groups in its workforce and leadership. The company has also been working to improve clinical trial diversity by enrolling more diverse patient populations in its clinical studies.

Jazz has faced scrutiny regarding the pricing of Xyrem, which has been among the most expensive drugs in the United States. The drug's list price has been estimated at over $70,000 per patient per year. Critics, including members of Congress and patient advocacy groups, have questioned the pricing of Xyrem and Xywav, particularly given that the active ingredient (sodium oxybate) has been available as a generic in some countries. Jazz has defended its pricing by citing the costs of clinical development, FDA-approved manufacturing, and risk evaluation and mitigation strategy (REMS) program requirements.

The company's patent strategies around Xyrem and Xywav have drawn attention from regulators and generic manufacturers. Jazz has been involved in patent litigation with generic manufacturers seeking to launch generic versions of sodium oxybate. The company has also faced scrutiny over its REMS program for Xyrem and Xywav, which restricts distribution to a single centralized pharmacy. Critics have argued that the REMS program creates a barrier to generic competition.

Jazz faced challenges related to the regulatory pathway for Defitelio, which initially received a Complete Response Letter from the FDA before ultimately gaining approval in 2016. The drug was approved in Europe in 2013 and in the United States in 2016, following additional clinical data submissions.

The acquisition of GW Pharmaceuticals in 2021 for $7.2 billion was controversial because it involved a cannabis-derived drug (Epidiolex) at a time when cannabis remained a Schedule I substance under US federal law. While Epidiolex itself was FDA-approved and descheduled, the association with cannabis created some reputational concerns for Jazz among conservative investor groups.

In 2024, Jazz received FDA approval for Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer, a rare indication. The approval was based on a single-arm trial, which some oncologists questioned as insufficient evidence for broad use. Jazz is conducting confirmatory trials to support full approval.